October 17, 2017 -
TORONTO, CANADA. MolecuLight, a global leader in fluorescence image-guidance solutions, is pleased to announce the appointment of industry veteran Anil Amlani as Chief Executive Officer effective September 29, 2017.
William Wignall, Chairman of the Board at MolecuLight, commented, “The Board is delighted to welcome Anil as MolecuLight’s new CEO. Anil
… Read MoreSeptember 16, 2016 -MolecuLight i:X wound care device instantly visualizes potentially harmful bacterial loads
TORONTO – September 16, 2016 – MolecuLight Inc. has received CE Mark approval authorizing commercial sales in the European Union of its MolecuLight i:X Imaging Device, that is revolutionizing wound care.
The MolecuLight i:X will be making its European debut at
… Read MoreJune 21, 2016 -This premier awards program for the medtech industry announced the 2016 winners
Toronto, June 21, 2016: The Medical Design Excellence Awards (MDEA), the premier awards program for the medtech industry announced the 2016 winners on Tuesday, June 14th at a special ceremony at the MD&M East conference and exposition in
… Read MoreOctober 20, 2015 -MolecuLight Inc. has been authorized to sell the MolecuLight i:X by Health Canada
TORONTO, Oct. 20, 2015 /CNW/ – MolecuLight ® Inc. has been authorized to sell the MolecuLight i:X by Health Canada. The approval will allow the company to begin selling the product throughout Canada. MolecuLight i:X is a novel, handheld fluorescence
… Read MoreNovember 28, 2014 -This important financial support will allow MolecuLight to accelerate commercialization
This important financial support will allow MolecuLight to accelerate commercialization of its unique patented handheld fluorescence-imaging platform, which will enable clinicians to detect bacteria in chronic wounds, in real-time and at the point-of-care. MolecuLight’s technology addresses an important problem in
… Read MoreNovember 7, 2014 -
Posted on November 07 , 2014
MolecuLight Inc. (Toronto, Canada) announced today a multi-project based research agreement with the University Health Network (UHN, Toronto, Canada) aimed at advancing their new handheld optical imaging technology enabling real-time bacterial imaging in wounds at the point-of-care.
Under the terms of the Agreement, MolecuLight Inc. will
… Read More
MolecuLight is SOC ll®
Type l Accredited:
MolecuLight awarded
Premier’s Technology
Breakthrough Designation
MolecuLight i:X
is designated as a:
MolecuLight included
in ISWCAP Consensus
Guidelines:
MolecuLight is a proud
corporate member of:
©2024
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.